Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Biochemical and Molecular Characterization of Marstacimab and TFPI PathwaysRelease Date:Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptomsRelease Date:Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence ApproachRelease Date:Research Inflammation & Immunology USA Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUCEducation Oncology USA Advancing Genomic Competence and Patient Centered Care in Metastatic Breast CancerRelease Date:Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction ManagementRelease Date:Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positRelease Date:Education Oncology United States Minor Outlying I OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic MalignanciesRelease Date:Quality Improvement Oncology China Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory OutcomeRelease Date:Education Vaccines USA Implementing Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Title Grant Type Focus Area Country Application Due Date Transition of Care in VTERelease Date:Anticoagulation Education - NVAF or VTERelease Date:Review Process:Achievement of Treat-to-Target in Rheumatoid ArthritisRelease Date:Improving Care of Chronic Pain- Physician Groups and Health SystemsRelease Date:Facilitation of the Diagnosis of Rheumatoid ArthritisRelease Date:Pfizer and NCCN: Metastatic Breast CancerRelease Date:Pediatric Immunization Series CompletionRelease Date:Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic ArthritisRelease Date:Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk PatientsRelease Date:Pfizer and American Academy of Dermatology (AAD): Patient Access to CareRelease Date:Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid ArthritisRelease Date: